In the 16-week clinical trials expected to start later this year — if the research method is given the nod by the QE II’s ethics committee — the researchers led by West and Khan will measure the effects of the drug apabetalone on 44 patients suffering with Fabry disease.
Dr. Michael West was featured in an article written by the Chronicle Herald. It is regarding Resverlogix and their research of Apabetalone.
Here is the link to the source: